Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Hjorth · SciRah

Researcher profile · Semantic Scholar

M. Hjorth

Share profile

M. Hjorth — researcher profile on SciRah

h-index: 30
Works: 50
Citations: 4,907

Most-cited papers

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
S. Pasquali, J. D. Maqueo, J. Vela, R. Kyle +64 more
1998Journal of Clinical Oncology533 citations
Semantic Scholar
Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
S. Schulman, P. Lindmarker, M. Holmström, G. Lärfars +11 more
2006Journal of Thrombosis and Haemostasis513 citations Open access
Semantic Scholar
A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism
S. Schulman, A. Rhedin, P. Lindmarker, A. Carlsson +13 more
1996419 citations
Semantic Scholar
Renal failure in multiple myeloma: reversibility and impact on the prognosis
L. Knudsen, M. Hjorth, E. Hippe
2000European Journal of Haematology413 citations
Semantic Scholar
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
S. Lenhoff, M. Hjorth, E. Holmberg, I. Turesson +14 more
2000Blood330 citations
Semantic Scholar
Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients
L. Knudsen, E. Hippe, M. Hjorth, E. Holmberg +1 more
1994European Journal of Haematology270 citations
Semantic Scholar
Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
C. Seidel, A. Sundan, M. Hjorth, I. Turesson +4 more
2000Blood260 citations
Semantic Scholar
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
A. Waage, P. Gimsing, P. Fayers, N. Abildgaard +21 more
2010Blood241 citations Open access
Semantic Scholar
Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study
M. Hjorth, Louise Hellquist, E. Holmberg, B. Magnusson +2 more
1993European Journal of Haematology213 citations
Semantic Scholar
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.
C. Seidel, O. Hjertner, N. Abildgaard, L. Heickendorff +7 more
2001Blood179 citations
Semantic Scholar
Measurement of health‐related quality of life in multiple myeloma
F. Wisløff, Sverre Eika, E. Hippe, M. Hjorth +4 more
1996British Journal of Haematology124 citations
Semantic Scholar
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
P. Gimsing, K. Carlson, I. Turesson, P. Fayers +18 more
2010The Lancet Oncology121 citations Open access
Semantic Scholar
Health‐related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma
F. Wislöff, M. Hjorth
1997British Journal of Haematology108 citations Open access
Semantic Scholar
Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study
J. Westin, S. Rödjer, I. Turesson, A. Cortelezzi +2 more
1995British Journal of Haematology101 citations
Semantic Scholar
Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myeloma
M. Stead, Julia M. Brown, G. Velikova, S. Kaasa +6 more
1999British Journal of Haematology90 citations
Semantic Scholar
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
N. Gulbrandsen, F. Wislöff, L. Brinch, K. Carlson +12 more
2001Medical Oncology85 citations
Semantic Scholar
Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group
S. Lenhoff, M. Hjorth, J. Westin, L. Brinch +14 more
2006British Journal of Haematology74 citations Open access
Semantic Scholar
Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferon
F. Wislöff, M. Hjorth, S. Kaasa, J. Westin
199669 citations
Semantic Scholar
Interferon- 2b Added to Melphalan-Prednisone for Initial and Maintenance Therapy in Multiple Myeloma
M. Hjorth, J. Westin, I. Dahl, P. Gimsing +11 more
1996Annals of Internal Medicine66 citations
Semantic Scholar
Toxicity in standard melphalan–prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment
K. Carlson, M. Hjorth, L. Knudsen
2005British Journal of Haematology64 citations
Semantic Scholar
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
S. Lenhoff, M. Hjorth, I. Turesson, J. Westin +15 more
2006Haematologica60 citations
Semantic Scholar
Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma
M. Hjorth, E. Holmberg, S. Rödjer, J. Westin
1992British Journal of Haematology57 citations
Semantic Scholar
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisone
M. Hjorth, Louise Hellquist, E. Holmberg, B. Magnusson +2 more
1990British Journal of Haematology54 citations
Semantic Scholar
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
M. Hjorth, O. Hjertner, L. Knudsen, N. Gulbrandsen +15 more
2012European Journal of Haematology49 citations Open access
Semantic Scholar
Cost–utility analysis of high‐dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
N. Gulbrandsen, F. Wisløff, E. Nord, S. Lenhoff +2 more
2001European Journal of Haematology40 citations
Semantic Scholar
Physicians' attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma.
M. Hjorth, E. Holmberg, S. Rödjer, Adam Taube +1 more
1996Controlled Clinical Trials37 citations
Semantic Scholar
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma
U. Mellqvist, S. Lenhoff, H. Johnsen, M. Hjorth +4 more
2008Cancer36 citations
Semantic Scholar
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma *
A. Waage, P. Gimsing, G. Juliusson, I. Turesson +7 more
2004British Journal of Haematology35 citations
Semantic Scholar
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades
M. Hjorth, E. Holmberg, S. Rödjer, I. Turesson +2 more
1999European Journal of Haematology31 citations
Semantic Scholar
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
F. Wisløff, M. Hjorth, S. Kaasa, J. Westin
1996British Journal of Haematology31 citations
Semantic Scholar
Legionnaires’ disease from a cooling tower in a community outbreak in Lidköping, Sweden- epidemiological, environmental and microbiological investigation supported by meteorological modelling
P. Ulleryd, A. Hugosson, G. Allestam, S. Bernander +9 more
2012BMC Infectious Diseases28 citations Open access
Semantic Scholar
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
F. Wisløff, N. Gulbrandsen, M. Hjorth, S. Lenhoff +1 more
2005European Journal of Haematology28 citations
Semantic Scholar
Transatlantic Trade and Investment Partnership
M. Hjorth
201625 citations
Semantic Scholar
A community outbreak of Legionnaires’ disease from an industrial cooling tower: Assessment of clinical features and diagnostic procedures
A. Hugosson, M. Hjorth, S. Bernander, B. Claesson +6 more
2007Scandinavian Journal of Infectious Diseases23 citations
Semantic Scholar
Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
C. Blimark, Ljupco Veskovski, J. Westin, S. Rödjer +5 more
2011European Journal of Haematology18 citations
Semantic Scholar
Serum calcium is an independent predictor of quality of life in multiple myeloma
F. Wisløff, A. K. Kvam, M. Hjorth, S. Lenhoff
2007European Journal of Haematology15 citations
Semantic Scholar
Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres
M. Hjorth, E. Holmberg, S. Rodjer, A. Taube +1 more
1995British Journal of Haematology14 citations
Semantic Scholar
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
J. Westin, A. Cortelezzi, M. Hjorth, S. Rödjer +2 more
1991European Journal of Cancer14 citations
Semantic Scholar
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
E. Nord, F. Wisløff, M. Hjorth, J. Westin
1997PharmacoEconomics (Auckland)11 citations
Semantic Scholar
Cost-Utility Analysis of Melphalan plus Prednisone With or Without Interferon-α2b in Newly Diagnosed Multiple Myeloma
E. Nord, F. Wisøff, M. Hjorth, J. Westin
1997PharmacoEconomics (Auckland)10 citations
Semantic Scholar
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life
E. Hellström-Lindberg, N. Gulbrandsen, Greger Lindberg, T. Ahlgren +16 more
2003British Journal of Haematology5 citations Open access
Semantic Scholar
Serologic Study of an Outbreak of Legionnaires’ Disease: Variation of Sensitivity Associated with the Subgroup of Legionella pneumophila sg1 Antigen Used and Evidence of Concurrent Reactivity to Other Atypical Pneumonia Agents
S. Bernander, B. Claesson, E. Hjelm, N. Svensson +1 more
20063 citations
Semantic Scholar
By-products from ethanol production - the forgotten part of the equation
H. Grinsted, M. Hjorth
20162 citations
Semantic Scholar
Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).
S. Lenhoff, M. Hjorth, P. Gimsing, J. Tangen +1 more
20042 citations
Semantic Scholar
Empiric treatment of fever in acute leukaemia with tobramycin-cephalothin, and the escape clause provision of corticosteroids.
M. Hjorth, A. Weinfeld, J. Brorson
1980Scandinavian Journal of Infectious Diseases2 citations
Semantic Scholar
Intensive Therapy in Multiple Myeloma. Long-Term Follow-Up with Focus on Relapse after Transplantation. The Nordic Myeloma Study Group (NMSG).
S. Lenhoff, M. Hjorth, J. L. Nielsen, I. Turesson +2 more
20041 citations
Semantic Scholar
Brain aging and electroconvulsive therapy
M. Hjorth, V. Frøkjær, M. B. Jørgensen, J. Macoveanu +1 more
2026Neuroscience Applied0 citations Open access
Semantic Scholar
with lytic bone disease Serum osteoprotegerin levels are reduced in patients with multiple myeloma
H. Hjorth-Hansen, A. Waage, A. Sundan, M. Børset +7 more
20130 citations
Semantic Scholar
Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.
U. Mellqvist, S. Lenhoff, M. Hjorth, E. Holmberg +4 more
20060 citations
Semantic Scholar
[High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
M. Hjorth, S. Lenhoff, I. Turesson, J. Westin
2000Läkartidningen0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Westin×19
Invite
J. Westin — researcher profile on SciRah
E. Holmberg×14
Invite
E. Holmberg — researcher profile on SciRah
I. Turesson×14
Invite
I. Turesson — researcher profile on SciRah
S. Lenhoff×13
Invite
S. Lenhoff — researcher profile on SciRah

×11

Invite

J. Westin — researcher profile on SciRah

Invite

P. Gimsing — researcher profile on SciRah

F. Wisløff×10

Invite

F. Wisløff — researcher profile on SciRah

J. L. Nielsen×9

Invite

J. L. Nielsen — researcher profile on SciRah

Invite

F. Wislöff — researcher profile on SciRah

Invite

S. Rödjer — researcher profile on SciRah

Invite

E. Hippe — researcher profile on SciRah

Invite

O. Linder — researcher profile on SciRah